281 related articles for article (PubMed ID: 30539030)
21. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
[TBL] [Abstract][Full Text] [Related]
22. Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.
Januel E; Hajage D; Labauge P; Maillart E; De Sèze J; Zephir H; Pelletier J; Guilloton L; Bensa C; Heinzlef O; Casez O; Biotti D; Bourre B; Vukusic S; Maurousset A; Berger E; Laplaud D; Lebrun-Frénay C; Dubessy AL; Branger P; Thouvenot E; Clavelou P; Sellal F; Manchon E; Moreau T; Papeix C; Tubach F; Louapre C
JAMA Netw Open; 2023 Jun; 6(6):e2319766. PubMed ID: 37351881
[TBL] [Abstract][Full Text] [Related]
23. Rescue Therapy Using Rituximab for Multiple Sclerosis.
Berenguer-Ruiz L; Sempere AP; Gimenez-Martinez J; Gabaldon-Torres L; Tahoces L; Sanchez-Perez R; Diaz-Marin C
Clin Neuropharmacol; 2016; 39(4):178-81. PubMed ID: 27046661
[TBL] [Abstract][Full Text] [Related]
24. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
[TBL] [Abstract][Full Text] [Related]
25. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
Costa-Frossard França L; Meca Lallana V; Labiano-Fontcuberta A; Blasco R; Monreal E; Martínez Ginés ML; Aguirre C; Sabin Muñoz J; Sainz de la Maza S; Cuello JP; Díaz-Pérez C; Chico García JL; Lozano Ros A; Rodríguez Jorge F; Martínez Martínez S; García Domínguez JM
CNS Drugs; 2024 Mar; 38(3):231-238. PubMed ID: 38418770
[TBL] [Abstract][Full Text] [Related]
26. Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysis.
Aungsumart S; Apiwattanakul M
Mult Scler Relat Disord; 2023 May; 73():104673. PubMed ID: 37001410
[TBL] [Abstract][Full Text] [Related]
27. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients.
Bellinvia A; Prestipino E; Portaccio E; Razzolini L; Fonderico M; Fratangelo R; Tudisco L; Pastò L; Amato MP
Neurol Sci; 2020 Oct; 41(10):2939-2945. PubMed ID: 32350672
[TBL] [Abstract][Full Text] [Related]
28. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Castillo-Trivino T; Braithwaite D; Bacchetti P; Waubant E
PLoS One; 2013; 8(7):e66308. PubMed ID: 23843952
[TBL] [Abstract][Full Text] [Related]
29. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Juto A; Fink K; Al Nimer F; Piehl F
Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of rituximab in refractory RRMS.
Durozard P; Maarouf A; Boutiere C; Ruet A; Brochet B; Vukusic S; Carra-Dalliere C; Labauge P; Mathey G; Debouverie M; Papeix C; Maillart E; Lubetzki C; Bensa C; Gout O; Giannesini C; Stankoff B; Ciron J; Brassat D; Pelletier J; Rico Lamy A; Audoin B
Mult Scler; 2019 May; 25(6):828-836. PubMed ID: 29722639
[TBL] [Abstract][Full Text] [Related]
31. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
Scotti B; Disanto G; Sacco R; Guigli M; Zecca C; Gobbi C
PLoS One; 2018; 13(5):e0197415. PubMed ID: 29758075
[TBL] [Abstract][Full Text] [Related]
33. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
34. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
35. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
[TBL] [Abstract][Full Text] [Related]
36. B-lymphocyte-guided retreatment contributes to establish good effectiveness and safety profile in MS patients treated with rituximab.
Chico-García JL; Rodríguez-Jorge F; Sainz-Amo R; Monreal E; Walo-Delgado P; Roldán E; Rodríguez-Martín E; Masjuan J; Costa-Frossard L; Sainz de la Maza S; Villar LM
Mult Scler Relat Disord; 2022 Dec; 68():104218. PubMed ID: 36270253
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
Havrdova E; Arnold DL; Cohen JA; Hartung HP; Fox EJ; Giovannoni G; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Rodriguez CE; Jody D; Hogan RJ; Xenopoulos P; Panzara MA; Coles AJ;
Neurology; 2017 Sep; 89(11):1107-1116. PubMed ID: 28835401
[TBL] [Abstract][Full Text] [Related]
38. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
39. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
Maarouf A; Rico A; Boutiere C; Perriguey M; Demortiere S; Pelletier J; Audoin B;
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32587103
[TBL] [Abstract][Full Text] [Related]
40. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X
Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
